PROMPT
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
What it measured
Main measures
The primary endpoint will be the mean number of cumulative combined unique active (CUA) lesions from week 4 to 24
MRI lesions
Other measures (1)
•Mean number of CUA at 4, 8, 12, 16, 20 and 24 weeks
Who could take part
Relapsing MS
Inclusion: •Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected information in accordance with local subject privacy regulations. Exclusion: •Primary progressive, secondary progressive, or progressive relapsing MS, as defined by Lublin and Reingold (Lublin and Reingold 1996)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of the study is to assess the early efficacy of treatment with BG00012 240 mg BID in the brain of newly diagnosed and naive-to-treatment patients with RRMS.
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TWINS
Phase 3 · Not yet recruiting
Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumar…
Recruiting
Still running
- SIMPLE
Stopped early
Stopped early
- A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of …
Phase 4 · Completed
No result found
- Prospective Evaluation of De-Escalation From antiCD-20 Th…
Running, not recruiting
Still running
History
Started
Apr 2015
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error